Misplaced Pages

BMB-101

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
5-HT2C receptor agonist

Pharmaceutical compound
BMB-101
Clinical data
Other namesBMB101
Routes of
administration
Oral
Drug classSerotonin 5-HT2C receptor agonist

BMB-101 is a serotonin 5-HT2C receptor agonist which is under development for the treatment of absence epilepsy, Pitt-Hopkins syndrome, Dravet syndrome, binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders. It is taken by mouth.

The drug acts as a highly selective biased agonist of the serotonin 5-HT2C receptor. It has greater that 100-fold selectivity for the serotonin 5-HT2C receptor over other serotonin receptors, including the serotonin 5-HT2A and 5-HT2B receptors. BMB-101 shows functional selectivity at the serotonin 5-HT2C receptor for activation of Gq signaling with minimal β-arrestin recruitment. This in turn appears to minimize receptor desensitization and development of tolerance. Due to its much greater selectivity for the serotonin 5-HT2C receptor, BMB-101 is not expected to possess the psychedelic effects or cardiotoxicity that have been associated with existing drugs like fenfluramine and lorcaserin at therapeutic or supratherapeutic doses. In accordance with its mechanism of action, BMB-101 produces anticonvulsant effects in animals.

BMB-101 is under development by Bright Minds Biosciences. As of October 2023, it is in phase 2 clinical trials for absence epilepsy and Pitt-Hopkins syndrome, phase 1 clinical trials for Dravet syndrome, and is in preclinical research for binge-eating disorder, Lennox-Gastaut syndrome, and opioid-related disorders. The chemical structure of BMB-101 does not yet appear to have been disclosed.

See also

References

  1. ^ "BMB 101". AdisInsight. 23 October 2024. Retrieved 30 October 2024.
  2. ^ "Delving into the Latest Updates on BMB-101 with Synapse". Synapse. 29 October 2024. Retrieved 30 October 2024.
  3. ^ Vasilkevich A, Duan J, Smith M, McCorvy JD, Pedersen J (May 2024). BMB-101: A selective 5-HT2C agonist for the treatment of rare epilepsies (PDF). Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII), Madrid, Spain 5 - 8 May 2024.
  4. ^ Vasilkevich A, Lovera A, Duan J, Smith MA, McCorvy J, Pedersen JT (October 2024). Selective 5-HT2C Agonists for the Treatment of Rare Epileptic Disorders (PDF). Society for Neuroscience 2024 Annual Meeting (Chicago), Satellite NIH Forum, October 5-9.
  5. ^ "Bright Minds Investor Deck" (PDF). Bright Minds Biosciences Inc. September 2024.
  6. ^ "Bright Minds Biosciences Launches Phase 2 Trial of BMB-101 for Epilepsy". Synapse. 14 September 2024. Retrieved 30 October 2024.

External links

Serotonin receptor modulators
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Categories:
BMB-101 Add topic